Getting Ipamorelin into the bloodstream
The name on an order identifies a molecule. The nasal-absorption experiments sent me looking for something less obvious: how it gets into the blood.
Nasal absorption in male rats
The nose was my unexpected starting place with Ipamorelin. In a 1998 study of nasal absorption in male rats, approximately 20% reached the bloodstream. Bioavailability is that fraction of an administered amount that reaches the circulation. The route had already changed the experiment before any hormone was measured.
I overestimated how much the chemical name could explain. Here was a practical obstacle sitting in front of it: getting the molecule into the body. A quantity in a preparation and a quantity circulating in blood answer different questions, even when the name on the preparation stays the same.
The same rat study reported 60–80% recovered unchanged in bile and urine. Those two findings concern entry and exit, respectively. I enjoy that unglamorous part of the story. A compound has a journey through an animal, complete with losses and departures; a receptor diagram shows only one stop.
Intravenous exposure in people
The published human pharmacokinetic study bypassed absorption from the nose or skin. Healthy men received Ipamorelin through a vein over 15 minutes. Growth hormone peaked at about 40 minutes, and the drug's terminal half-life was approximately 2 hours. That gives the blood measurements a specific setting.
Intravenous delivery also appeared in the published bowel-surgery trial. That trial missed its primary endpoint, the time to a first tolerated meal. Getting a drug into circulation and showing that it improves a patient's recovery are separate experimental tasks. Both deserve an answer.
The intravenous research page follows those human experiments. The study amounts page puts route and amount beside each other.
Under the skin
Community accounts commonly describe subcutaneous use, meaning delivery under the skin. Yet the published human record lacks safety and pharmacokinetic characterization for that route. The nasal percentage from male rats cannot fill the gap, and neither can the intravenous half-life in healthy men.
The missing exposure data make an assurance about that preparation premature. Before discussing sleep, recovery or a leaner appearance, I want an account of the exposure it produces. Anecdotal accounts describe all those hoped-for changes; they provide no clinical evidence of a reliable effect. The effects page also includes the less welcome reports.
Preparation and approval
Ipamorelin has never been approved as a medicine. The review of its unresolved safety and efficacy questions leaves a long way between an interesting hormone response and established care. Preparation adds questions of identity, purity and sterility, which a chemical name alone cannot settle.
On FDA's page current as of April 22, 2026, Ipamorelin acetate's nomination is withdrawn under 503A. It remains in Category 2 under 503B for outsourcing facilities, and FDA retains its safety concerns. No withdrawal date is given. Those entries leave the approval status unchanged.
The mechanism explains why the molecule interested researchers in the first place. Its passage into the bloodstream remains an absorbing question.